The Esophageal Cancer Drug Market in China Will Almost Double, Growing From $75 Million in 2009 to $149 Million in 2014

Factors Driving Growth Will Include Improved Access To Medical Care For Patients and a Growing Drug-Treated Population, According to a New Report from Decision Resources

WALTHAM, Mass., May 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the Chinese esophageal cancer drug market will almost double, growing from $75 million in 2009 to $149 million in 2014. Growth will be driven by improved access to medical care, a growing drug-treated population and a rising number of higher-income esophageal cancer patients driving the demand for more-efficacious agents.

The new Emerging Markets report entitled Esophageal Cancer in China finds that the use of targeted therapies in esophageal cancer in China will increase as more results from clinical studies become available through 2014. Chinese oncologists report that the key targeted therapies they use to treat esophageal cancer are Shandong Simcere Medgenn's Endostar, AstraZeneca's Iressa and Roche's Tarceva.  

"Additionally, through 2014, we expect that two other targeted therapies -- Merck KGaA's Erbitux and Roche's Avastin -- will be used to treat esophageal cancer in China," said Jing Wu, M.S., MBA. "However, uptake of both of these agents will be modest, and Erbitux will face generic competition beginning in 2014."

Newly diagnosed cases of esophageal cancer in China are expected to increase by almost 1 percent per year through 2014. The report also finds that 67 percent of esophageal cancer cases are diagnosed in advanced stages of the disease (stage III or IV). The report contains primary research of physicians and epidemiology in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and also provides the epidemiology study in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou and Jinan.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:


Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]




SOURCE Decision Resources

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.